FeesSafety
Pluang+

Renaissance IPO ETF remains a Buy despite recent lag; Anthropic's debut seen as key catalyst.

Market News
16 Nov 2026, 21:31 WIB
Seeking Alpha
View Source
Bullish
Renaissance IPO ETF remains a Buy despite recent lag; Anthropic's debut seen as key catalyst.

The Renaissance IPO ETF is recommended as a Buy, even though its shares have underperformed since May. It trades at a reasonable 15.3 times earnings with a strong long-term earnings growth rate above 9%. The upcoming IPO of Anthropic PBC, expected to start trading on November 19, is anticipated to be a significant positive catalyst for the ETF's portfolio. However, risks include AI sector volatility, potential data-center restrictions, and increased scrutiny on chip trades, with the ETF's top 10 holdings making up 57% of assets. Technically, the ETF is near its uptrend support but shows some weakness in momentum indicators and faces resistance in the mid-to-high $60 range.

The Renaissance IPO ETF is noted with a strong long-term earnings growth rate above 9%, providing context for this IPO-focused story. For readers following Technology-sector US stocks on Pluang, here is the market snapshot as of Nov 17, 2026 02:12 WIB: out of 150 stocks, 33 rose and 116 fell today. Notable movers include NBIS at USD 107.05 with a -7.62% change and a typical hold time of 28 days, MSTR at USD 103.33 down 7.43% with a 116-day hold, and CRDO at USD 122.01 down 7.22% with a 26-day hold and 85% buy order activity.

More News

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
44 minutes ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
1 hour ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
2 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
2 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 in early November 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 in early November 2026

Rexel Développement SAS announced it bought back a total of 3,878 of its own shares between November 9 and 13, 2026, at an average price of €34.67 per share. This share repurchase is part of the authorization granted by its shareholders to operate on...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App